Becton Dickinson and Co (NYSE:BDX) Director Timothy M. Ring sold 42,000 shares of Becton Dickinson and stock in a transaction on Wednesday, November 7th. The shares were sold at an average price of $237.07, for a total value of $9,956,940.00. Following the transaction, the director now owns 93,688 shares of the company’s stock, valued at approximately $22,210,614.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
BDX stock opened at $243.26 on Friday. Becton Dickinson and Co has a 1-year low of $209.91 and a 1-year high of $265.87. The company has a debt-to-equity ratio of 0.95, a current ratio of 1.23 and a quick ratio of 0.81. The firm has a market capitalization of $64.40 billion, a PE ratio of 22.09, a price-to-earnings-growth ratio of 1.44 and a beta of 1.19.
Becton Dickinson and (NYSE:BDX) last posted its quarterly earnings results on Tuesday, November 6th. The medical instruments supplier reported $2.93 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $2.93. Becton Dickinson and had a return on equity of 13.84% and a net margin of 1.47%. The firm had revenue of $4.40 billion during the quarter, compared to analysts’ expectations of $4.36 billion. During the same quarter in the previous year, the business earned $2.40 earnings per share. The company’s revenue was up 39.0% on a year-over-year basis. As a group, research analysts anticipate that Becton Dickinson and Co will post 12.28 EPS for the current fiscal year.
A number of research analysts have issued reports on BDX shares. KeyCorp reiterated a “buy” rating and set a $264.00 price objective on shares of Becton Dickinson and in a research note on Friday, August 3rd. Citigroup lifted their price objective on Becton Dickinson and from $274.00 to $283.00 and gave the company a “buy” rating in a research note on Wednesday, August 8th. Barclays started coverage on Becton Dickinson and in a research note on Monday, October 15th. They set an “equal weight” rating and a $278.00 price objective for the company. Morgan Stanley lifted their price objective on Becton Dickinson and from $250.00 to $280.00 and gave the company an “equal weight” rating in a research note on Thursday, October 4th. Finally, Royal Bank of Canada reiterated a “hold” rating and set a $248.00 price objective on shares of Becton Dickinson and in a research note on Friday, August 3rd. Five investment analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $254.07.
ILLEGAL ACTIVITY NOTICE: “Timothy M. Ring Sells 42,000 Shares of Becton Dickinson and Co (BDX) Stock” was first posted by WKRB News and is the sole property of of WKRB News. If you are reading this story on another site, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be read at https://www.wkrb13.com/2018/11/10/timothy-m-ring-sells-42000-shares-of-becton-dickinson-and-co-bdx-stock.html.
About Becton Dickinson and
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.
Featured Article: Investing in Growth Stocks
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.